Mortality Advantage With Pimavanserin in Parkinson's Psychosis?

Use of pimavanserin was associated with 35% lower mortality for patients with Parkinson's disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.

Related Keywords

United States ,American ,Pimavanserin Nuplazid ,Andrew Mosholder ,Acadia Pharmaceuticals ,Drug Administration ,Drug Evaluation ,Medscape Medical ,American Journal ,Medscape Medical News ,Parkinsons Disease ,Psychosis ,Depression ,Atypical Antipsychotics ,Schizophrenia ,Delusion ,Hallucination ,Nursing Homes ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Off Label Indication ,